Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy (RELEASE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ashford, United Kingdom
- Research Site
-
Atherstone, United Kingdom
- Research Site
-
Ayrshire, United Kingdom
- Research Site
-
Bath, United Kingdom
- Research Site
-
Blackpool, United Kingdom
- Research Site
-
Bolton, United Kingdom
- Research Site
-
Cardiff, United Kingdom
- Research Site
-
Carrickfergus, United Kingdom
- Research Site
-
Cheshire, United Kingdom
- Research Site
-
Chesterfield, United Kingdom
- Research Site
-
Coventry, United Kingdom
- Research Site
-
Dundee, United Kingdom
- Research Site
-
Ellesmere Port, United Kingdom
- Research Site
-
Fife, United Kingdom
- Research Site
-
Glasgow, United Kingdom
- Research Site
-
Harrow, United Kingdom
- Research Site
-
Larne, United Kingdom
- Research Site
-
Leeds, United Kingdom
- Research Site
-
Middlesborough, United Kingdom
- Research Site
-
Newcastle, United Kingdom
- Research Site
-
Newtownabbey, United Kingdom
- Research Site
-
Peterhead, United Kingdom
- Research Site
-
Pontypridd, United Kingdom
- Research Site
-
Reading, United Kingdom
- Research Site
-
Rugby, United Kingdom
- Research Site
-
Rutherglen, United Kingdom
- Research Site
-
Sandy, United Kingdom
- Research Site
-
Sheffield, United Kingdom
- Research Site
-
Stafford, United Kingdom
- Research Site
-
Stevenage, United Kingdom
- Research Site
-
Stockport, United Kingdom
- Research Site
-
Sunbury on Thames, United Kingdom
- Research Site
-
Sutton Coldfield, United Kingdom
- Research Site
-
Tilehurst, United Kingdom
- Research Site
-
Tonbridge, United Kingdom
- Research Site
-
Trowbridge, United Kingdom
- Research Site
-
Vale of Glamorgan, United Kingdom
- Research Site
-
Warminster, United Kingdom
- Research Site
-
Watford, United Kingdom
- Research Site
-
Wells next the Sea, United Kingdom
- Research Site
-
Westbury, United Kingdom
- Research Site
-
Woking, United Kingdom
- Research Site
-
Yaxley, United Kingdom
- Research Site
-
-
Cornwall
-
Fowey, Cornwall, United Kingdom
- Research Site
-
-
East Sussex
-
Hove, East Sussex, United Kingdom
- Research Site
-
-
Essex
-
Ilford, Essex, United Kingdom
- Research Site
-
-
Fife
-
Glenrothes, Fife, United Kingdom
- Research Site
-
-
Kent
-
Dartford, Kent, United Kingdom
- Research Site
-
-
Lanarkshire
-
Airdrie, Lanarkshire, United Kingdom
- Research Site
-
Hamilton, Lanarkshire, United Kingdom
- Research Site
-
-
North Yorkshire
-
Doncaster, North Yorkshire, United Kingdom
- Research Site
-
-
Northern Ireland
-
Cookstown, Northern Ireland, United Kingdom
- Research Site
-
Downpatrick, Northern Ireland, United Kingdom
- Research Site
-
-
South Glamorgan
-
Barry, South Glamorgan, United Kingdom
- Research Site
-
-
Staffordshire
-
Chase Terrace, Staffordshire, United Kingdom
- Research Site
-
-
Surrey
-
East Horsley, Surrey, United Kingdom
- Research Site
-
-
West Sussex
-
Crawley, West Sussex, United Kingdom
- Research Site
-
-
Wiltshire
-
Box, Wiltshire, United Kingdom
- Research Site
-
Bradford-On-Avon, Wiltshire, United Kingdom
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged over 18
- Confirmed diagnosis of mild to moderate asthma by doctor
- Currently receiving inhaled corticoid-steroid medicine for treatment of asthma and requiring a review of current asthma treatment
Exclusion Criteria:
- Women who are pregnant, breast-feeding, or planning pregnancy
- Patients with a history of chronic obstructive pulmonary disease
- Patients using any beta blocker therapy
- Patients receiving steroid tablets or steroid injections
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
In a real life setting, to compare Symbicort® Single Inhaler Therapy with a patient's previous therapy (including low dose ICS), by assessment of the changes in the Asthma Control Questionnaire score in uncontrolled asthmatic patients.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Change in forced expiratory volume in one second (FEV1)
|
|
Change in peak expiratory flow (PEF)
|
|
Patient Reported Outcomes: AQLQ(S), SATQ, RCP-3 scores
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Iain Small, MD, General Practitioner
- Study Director: AstraZeneca UK Medical Director, MD, AstraZeneca
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Budesonide
- Formoterol Fumarate
- Budesonide, Formoterol Fumarate Drug Combination
Other Study ID Numbers
Other Study ID Numbers
- D5890L00012
- RELEASE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
NCT07412769RecruitingAsthma in Children | Asthma Acute | Asthma Crisis | Asthma Childhood
-
NCT07629830Not yet recruitingAsthma Attack | Asthma Acute
-
NCT07261423RecruitingAsthma Exacerbation | Childhood Asthma | Air Pollution, Risk Reduction Behaviors | Asthma Control
-
NCT03277170WithdrawnAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; Status
-
NCT03642418CompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
NCT07582211Not yet recruitingAcute Asthma | Pediatric Asthma | Non-invasive Positive Pressure Ventilation | BiPAP
-
NCT06377345RecruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
NCT07600190Not yet recruitingPersistent Asthma | Asthma (Diagnosis) | Moderate Asthma Exacerbation
Clinical Trials on Budesonide/formoterol
-
NCT07414134CompletedChronic Obstructive Pulmonary Disease
-
NCT06590740Completed
-
NCT07595796Not yet recruitingPreserved Ratio Impaired Spirometry (PRISM)
-
NCT00868426Completed
-
NCT01179152Unknown
-
NCT07318350Not yet recruiting
-
NCT04183881CompletedPsoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma
-
NCT00419744CompletedChronic Obstructive Pulmonary Disease